Table 1.

Estimated overall survival probability at specified time-points (final analysis).

Time-point (months)	Overall survival probability (95% CI)
	TT-B (n = 77)	C-B (n = 76)
6	0.86 (0.76–0.92)	0.83 (0.72–0.90)
12	0.76 (0.65–0.84)	0.67 (0.55–0.76)
18	0.63 (0.51–0.73)	0.47 (0.35–0.57)
24	0.39 (0.28–0.50)	0.34 (0.24–0.45)

C-B capecitabine plus bevacizumab, CI confidence interval, TT-B trifluridine/tipiracil plus bevacizumab.